Brian Marckx, CFA
Long/short equity

Sanuwave: DermaPACE Could Be Very Competitive In $2B Diabetic Foot Ulcer Market


Sanuwave Health, Inc. (OTCQB:SNWV) is developing non-invasive medical devices using its proprietary Pulsed Acoustic Cellular Expression (PACE) technology to aid in the body's repair and regeneration of tissue, musculoskeletal and vascular structures. PACE works by creating shock waves which, in-turn, elicit a biological response and help the healing process.

Recent clinical studies have indicated the company's lead product, dermaPACE, is more effective than current standard of care in the treatment of serious life-threatening diabetic foot ulcers (DFU). In July 2011 Sanuwave made the third and final module filing of a three-tiered PMA application seeking FDA approval of dermaPACE for the treatment of diabetic foot ulcers. Surprisingly, the FDA responded in December 2011 with a major deficiency letter,

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details